-
公开(公告)号：US20090318350A1
公开(公告)日：2009-12-24
申请号：US12398281
申请日：2009-03-05
CPC分类号： C07K14/485 , A61K38/00
摘要： The present invention features human epidermal receptor (HER) antagonists. These antagonists are polypeptide variants of ligands of HER. The HER ligand polypeptide variants of the invention possess Pan-HER antagonistic properties and can inhibit at least one HER-mediated biological activity of one or more HER subtypes, such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of HER activity is indicated.
摘要翻译： 本发明特征在于人表皮受体（HER）拮抗剂。 这些拮抗剂是HER的配体的多肽变体。 本发明的HER配体多肽变体具有Pan-HER拮抗特性，并且可以抑制至少一种HER介导的一种或多种HER亚型的生物学活性，例如受体激酶活化活性的抑制和随后的细胞增殖。 这些多肽变体和编码这些多肽变体的核酸可以在其中指示HER活性的抑制的情况下治疗地使用。
-
公开(公告)号：US07557181B2
公开(公告)日：2009-07-07
申请号：US11172611
申请日：2005-06-30
IPC分类号： C07K14/475 , C07K14/485
CPC分类号： C07K14/475 , A61K38/1808 , C07K14/4756 , C07K14/485 , C07K14/495
摘要： The present invention features human epidermal receptor (HER) antagonists. These antagonists are polypeptide variants of ligands of HER. The HER ligand polypeptide variants of the invention possess Pan-HER antagonistic properties and can inhibit at least one HER-mediated biological activity of one or more HER subtypes, such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of HER activity is indicated.
摘要翻译： 本发明特征在于人表皮受体（HER）拮抗剂。 这些拮抗剂是HER的配体的多肽变体。 本发明的HER配体多肽变体具有Pan-HER拮抗特性，并且可以抑制至少一种HER介导的一种或多种HER亚型的生物学活性，例如受体激酶活化活性的抑制和随后的细胞增殖。 这些多肽变体和编码这些多肽变体的核酸可以在其中指示HER活性的抑制的情况下治疗地使用。
-
公开(公告)号：US20090311783A1
公开(公告)日：2009-12-17
申请号：US12398269
申请日：2009-03-05
IPC分类号： C07K14/475 , C12N5/06
摘要： The present invention relates to IGF-I variants that bind to the Insulin-like Growth Factor Receptor I (IGF-IR) but do not initiate signal transduction and the subsequent metabolic, growth and anti-apoptotic activities associated with this molecule and the progression of cancer. These novel variants act to block the binding of the cognate ligands but do not bind to the insulin receptor.
摘要翻译： 本发明涉及结合胰岛素样生长因子受体I（IGF-1R）但不启动信号转导的IGF-1变体，以及与该分子相关的随后的代谢，生长和抗凋亡活性 癌症。 这些新型变体用于阻断同源配体的结合，但不结合胰岛素受体。
-
公开(公告)号：US20090286729A1
公开(公告)日：2009-11-19
申请号：US12261233
申请日：2008-10-30
IPC分类号： A61K38/16 , C07K14/485 , A61P35/00 , A61P17/06
CPC分类号： A61K38/1808 , A61K38/00 , C07K14/475
摘要： The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.
摘要翻译： 本发明具有表皮生长因子受体（EGFR）拮抗剂。 这些EGFR拮抗剂是EGFR的配体的多肽变体。 本发明的EGFR配体多肽变体具有EGFR拮抗性，并且可以抑制至少一种EGFR介导的生物活性，例如抑制受体的激酶活化活性，随后抑制细胞增殖。 这样的多肽变体和编码这些多肽变体的核酸可以在其中指示EGFR活性的抑制的情况下治疗地使用。
-
公开(公告)号：US07470769B2
公开(公告)日：2008-12-30
申请号：US11172610
申请日：2005-06-30
IPC分类号： C07K14/475 , C07K14/485 , C07K14/495
CPC分类号： A61K38/1808 , A61K38/00 , C07K14/475
摘要： The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated.
摘要翻译： 本发明具有表皮生长因子受体（EGFR）拮抗剂。 这些EGFR拮抗剂是EGFR的配体的多肽变体。 本发明的EGFR配体多肽变体具有EGFR拮抗性，并且可以抑制至少一种EGFR介导的生物活性，例如抑制受体的激酶活化活性，随后抑制细胞增殖。 这样的多肽变体和编码这些多肽变体的核酸可以在其中指示EGFR活性的抑制的情况下治疗地使用。
-
-
-
-
搜索结果
5 条记录 (耗时 0.01 秒)
